IRulya Therapeutics, Inc. (IRLA)
40.65
+0.71
(+1.78%)
USD |
NASDAQ |
Nov 20, 10:35
IRulya Therapeutics Cash from Operations (Quarterly) : -9.84M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -9.84M |
| June 30, 2026 | -18.89M |
| March 31, 2026 | -7.627M |
| December 31, 2025 | -10.48M |
| September 30, 2025 | -9.928M |
| June 30, 2025 | -11.42M |
| March 31, 2025 | -9.601M |
| December 31, 2024 | -7.552M |
| September 30, 2024 | -7.26M |
| June 30, 2024 | -8.739M |
| March 31, 2024 | -8.353M |
| December 31, 2023 | -6.078M |
| September 30, 2023 | -4.818M |
| June 30, 2023 | -3.827M |
| March 31, 2023 | -3.569M |
| December 31, 2022 | -5.835M |
| September 30, 2022 | -6.697M |
| June 30, 2022 | -15.42M |
| Date | Value |
|---|---|
| March 31, 2022 | -16.09M |
| December 31, 2021 | -14.42M |
| September 30, 2021 | -17.34M |
| June 30, 2021 | -17.56M |
| March 31, 2021 | -13.61M |
| December 31, 2020 | -13.28M |
| September 30, 2020 | -12.37M |
| June 30, 2020 | -14.39M |
| March 31, 2020 | -10.78M |
| December 31, 2019 | -10.95M |
| September 30, 2019 | -8.796M |
| June 30, 2019 | -6.315M |
| March 31, 2019 | -7.216M |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | -2.62M |
| March 31, 2018 | -3.177M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Korsana Biosciences, Inc. | -46.83M |
| PepGen Inc. | -13.18M |
| Q32 Bio, Inc. | -4.418M |
| Bridgebio Oncology Therapeutics, Inc. | -28.36M |
| Oncolytics Biotech, Inc. | -6.754M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -67.79M |
| Cash from Financing (Quarterly) | -0.01M |
| Free Cash Flow | -46.91M |
| Free Cash Flow Per Share (Quarterly) | -0.8256 |
| Free Cash Flow to Equity (Quarterly) | -9.911M |
| Free Cash Flow to Firm (Quarterly) | -9.911M |
| Free Cash Flow Yield | -113.5% |